Dopamine transporter density is decreased in Parkinsonian patients with a history of manganese exposure: What does it mean?

Movement Disorders

Volumn 17, Issue 3, 2002, Pages 568-575

  Kim, Y ^a   Kim, J M ^b   Kim, J W ^c   Yoo, C I ^a   Lee, C R ^a   Lee, J H ^a   Kim, H K ^a   Yang, S O ^a   Chung, H K ^d   Lee, D S ^e   Jeon, B S ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Dong A University   (South Korea)

^d Korea Occupational Safety and Health Agency   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

CIT SPECT; Dopamine transporter; Idiopathic Parkinson disease; Manganese; Parkinsonism

Indexed keywords

DOPAMINE TRANSPORTER; IODINE 123; MANGANESE; TROPANE DERIVATIVE;

ADULT; ARTICLE; BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; GLOBUS PALLIDUS; HUMAN; INTERMETHOD COMPARISON; MALE; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL EXPOSURE; PARKINSON DISEASE; PARKINSONISM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RISK ASSESSMENT; URINE LEVEL;

CAUSALITY; COCAINE; CORPUS STRIATUM; DIAGNOSIS, DIFFERENTIAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; IODINE RADIOISOTOPES; MALE; MANGANESE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; OCCUPATIONAL EXPOSURE; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0036589896     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10089     Document Type: Article

References (48)

1. Huang CC, Chu NS, Lu CS, Wang JD, Tsai JL, Tzeng JL, Wolters EC, Calne DB. Chronic manganese intoxication. Arch Neurol 1989;46:1104-1106.
2. Calne DB, Chu NS, Huang CC, Lu CS, Olanow W. Manganism and idiopathic parkinsonism: similarities and differences. Neurology 1994;44:1583-1586.
3. Huang CC, Lu CS, Chu NS, Hochberg F, Lilienfeld D, Olanow W, Calne DB. Progression after chronic manganese exposure. Neurology 1993;43:1479-1483.
4. Ashizawa R. Uber einen sektionsfall von chronischer manganvergiftung. Jap J Med Sci Trans, Sect VIII - Int Med Pediat Psychiat 1927;1:173-191.
5. Flintzer H. Uber gewerbliche manganvergiftung. Arch f Psychiat 1931;93:84-115.
6. Canavan MM, Cobb S, Drinker CK. Chronic manganese poisoning: report of a case with autopsy. Arch Neurol Psychiatry 1934; 32:501-512.
7. Stadler HZ. Zur histopathologie des gehirns bei manganvergiftung. Zbl Ges Neurol Psychiat 1935-1936;154:62-76.
8. Trendtel I. Zur frage des manganismus. Mschr Unfallheilk 1936; 43:69-84.
9. Voß H. Progressive bulbärparalyse und amyotrophische lateralsklerose nach chronischer manganvergiftung. Arch Gewerbepath Gewerbehyg 1939;9:464-476.
10. Scholten JM. On manganese encephalopathy. Folia Psychiatr Neurol 1953;56:878-884.
11. Parnitzke KH, Peiffer J. Zur klinik und pathologischen anatomie der chronischen braunsteinvergiftung. Arch Psychiat Nervenkr 1954;192:405-429.
12. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455.
13. Yamada M, Ohno S, Okayasu I, Okeda R, Hatakeyama S, Watanabe H, Ushio K, Tsukagoshi H. Chronic manganese poisoning: a neuropathological study with determination of manganese distribution in the brain. Acta Neuropathol (Berl) 1986;70:273-278.
14. Yong VW, Perry TL, Godolphin WJ, Jones KA, Clavier RM, Ito M, Foulks JG. Chronic organic manganese administration in the rat does not damage dopaminergic nigrostriatal neurons. Neurotoxicology 1986;7:19-24.
15. Shinotoh H, Snow BJ, Hewitt KA, Pate BD, Doudet D, Nugent R, Perl DP, Olanow W, Calne DB. MRI and PET studies of manganese-intoxicated monkeys. Neurology 1995;45:1199-1204.
16. Olanow CW, Good PF, Shinotoh H, Hewitt KA, Vingerhoets F, Snow BJ, Beal MF, Calne DB, Perl DP. Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study. Neurology 1996;46:492-498.
17. 123I]-β-CIT SPECT: Pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13: 295-309.
18. 123I]-β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
19. 123I]-β-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 1998;43:792-800.
20. 123I]-β-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease. J Neurol Neurosurg Psychiatry 1998;65:60-64.
21. Wolters EC, Huang CC, Clark C, Peppard RF, Okada J, Chu NS, Adam MJ, Ruth TJ, Li D, Calne DB. Positron emission tomography in manganese intoxication. Ann Neurol 1989;26:647-651.
22. National Institute for Occupational Safety and Health (NIOSH). NIOSH manual of analytical methods (NMAM), fourth ed., Department of Health and Human Services Publication No. 94-113. Cincinnati, OH: NIOSH, 1994.
23. Early detection of occupational diseases. Geneva: World Health Organization; 1986.
24. Kim Y, Kim JW, Ito K, Lim HS, Cheong HK, Kim JY, Shin YC, Kim KS, Moon Y. Idiopathic parkinsonism with superimposed manganese exposure: utility of positron emission tomography. Neurotoxicology 1999;20:249-252.
25. Gupta SK, Murthy RC, Chandra SV. Neuromelanin in manganese-exposed primates. Toxicol Lett 1980;6:17-20.
26. Eriksson H, Gillberg PG, Aquilonius SM, Hedström KG, Heilbronn E. Receptor alterations in manganese intoxicated monkeys. Arch Toxicol 1992;66:359-364.
27. Eriksson H, Tedroff J, Thuomas KA, Aquilonius SM, Hartvig P, Fasth KJ, Bjurling P, Lángström B, Hedström KG, Heilbronn E. Manganese induced brain lesions in Macaca fascicularis as revealed by positron emission tomography and magnetic resonance imaging. Arch Toxicol 1992;66:403-407.
28. Duchen LW, Jacobs J. Nutritional deficiencies and metabolic disorders. In: Adams JH, Duchen LW, editors. Greenfield's Neuropathology. fifth ed. London: Edward Arnold, 1992. p 838-841.
29. Barbeau A, Friesen H. Treatment of Wilson's disease with L-dopa after failure with penicillamine. Lancet 1970;1:1180-1181.
30. Westermark K, Tedroff J, Thuomas KA, Hartvig P, Langstrom B, Andersson Y, Hornfeldt K, Aquilonius SM. Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers. Mov Disord 1995;10:596-603.
31. Cotzias GC. Metabolic modification of some neurologic disorders. JAMA 1969;210:1255-1262.
32. Mena I, Court J, Fuenzalida S, Papavasiliou PS, Cotzias GC. Modification of chronic manganese poisoning. Treatment with L-dopa or 5-OH tryptophane. N Engl J Med 1970;282:5-10.
33. Huang CC, Chu NS, Lu CS, Chen RS, Calne DB. Long-term progression in chronic manganism. Ten years of follow-up. Neurology 1998;50:698-700.
34. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999;46:598-605.
35. Palfi S, Leventhal L, Goetz CG, Hantraye T, Roitberg BZ, Sramek J, Emborg M, Kordower JH. Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys. Mov Disord 2000;15:524-530.
36. -. Free Radic Biol Med 1986;2:3-11.
37. Gerlach M, Ben-Shachar D, Riederer P, Youdim MB. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994;63:793-807.
38. Barbeau A. Manganese and extrapyramidal disorders (a critical review and tribute to Dr. George C. Cotzias). Neurotoxicology 1984;5:13-35.
39. Montine TJ, Farris DB, Graham DG. Covalent crosslinking of neurofilament proteins by oxidized catechols as a potential mechanism of Lewy body formation. J Neuropathol Exp Neurol 1995; 54:311-319.
40. Rybicki BA, Johnson CC, Uman J, Gorell JM. Parkinson's disease mortality and the industrial use of heavy metals in Michigan. Mov Disord 1993;8:87-92.
41. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, Richardson RJ. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 1997;48:650-658.
42. Semchuk KM, Love EJ, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993;43:1173-1180.
43. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-1975.
44. Bird ED, Anton AH, Bullock B. The effect of manganese inhalation on basal ganglia dopamine concentrations in rhesus monkey. Neurotoxicology 1984;5:59-65.
45. Nelson K, Golnick J, Korn T, Angle C. Manganese encephalopathy: utility of early magnetic resonance imaging. Br J Ind Med 1993;50:510-513.
46. Kim Y, Kim KS, Yang JS, Park IJ, Kim E, Jin Y, Kwon KR, Chang KH, Kim JW, Park SH, Lim HS, Cheong HK, Shin YC, Park J, Moon Y. Increase in signal intensities on T1-weighted magnetic resonance images in asymptomatic manganese-exposed workers. Neurotoxicology 1999;20:901-907.
47. Mirowitz SA, Westrich TJ, Hirsch JD. Hyperintense basal ganglia on T1-weighted MR images in patients receiving parenteral nutrition. Radiology 1991;181:117-120.
48. Hauser RA, Zesiewicz TA, Rosemurgy AS, Martinez C, Olanow CW. Manganese intoxication and chronic liver failure. Ann Neurol 1994;36:871-875.